These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
514 related articles for article (PubMed ID: 34867942)
1. Solid Tumor Microenvironment Can Harbor and Support Functional Properties of Memory T Cells. Sullivan PM; Reed SJ; Kalia V; Sarkar S Front Immunol; 2021; 12():706150. PubMed ID: 34867942 [TBL] [Abstract][Full Text] [Related]
2. Astragalus polysaccharide enhances antitumoral effects of chimeric antigen receptor- engineered (CAR) T cells by increasing CD122 Zhang Q; Su C; Luo Y; Zheng F; Liang CL; Chen Y; Liu H; Qiu F; Liu Y; Feng W; Dai Z Biomed Pharmacother; 2024 Oct; 179():117401. PubMed ID: 39243425 [TBL] [Abstract][Full Text] [Related]
3. Tissue-resident memory CD8 Wang T; Shen Y; Luyten S; Yang Y; Jiang X Pharmacol Res; 2020 Sep; 159():104876. PubMed ID: 32422340 [TBL] [Abstract][Full Text] [Related]
4. The TOPK Inhibitor HI-TOPK-032 Enhances CAR T-cell Therapy of Hepatocellular Carcinoma by Upregulating Memory T Cells. Zhang Q; Zheng F; Chen Y; Liang CL; Liu H; Qiu F; Liu Y; Huang H; Lu W; Dai Z Cancer Immunol Res; 2024 May; 12(5):631-643. PubMed ID: 38407902 [TBL] [Abstract][Full Text] [Related]
6. CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape. Rodriguez-Garcia A; Palazon A; Noguera-Ortega E; Powell DJ; Guedan S Front Immunol; 2020; 11():1109. PubMed ID: 32625204 [TBL] [Abstract][Full Text] [Related]
7. Future perspectives on engineered T cells for cancer. Posey AD; Young RM; June CH Trends Cancer; 2024 Aug; 10(8):687-695. PubMed ID: 38853073 [TBL] [Abstract][Full Text] [Related]
8. Bystander activation and anti-tumor effects of CD8+ T cells following Interleukin-2 based immunotherapy is independent of CD4+ T cell help. Monjazeb AM; Tietze JK; Grossenbacher SK; Hsiao HH; Zamora AE; Mirsoian A; Koehn B; Blazar BR; Weiss JM; Wiltrout RH; Sckisel GD; Murphy WJ PLoS One; 2014; 9(8):e102709. PubMed ID: 25119341 [TBL] [Abstract][Full Text] [Related]
9. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Martinez M; Moon EK Front Immunol; 2019; 10():128. PubMed ID: 30804938 [TBL] [Abstract][Full Text] [Related]
10. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells. Gowrishankar K; Birtwistle L; Micklethwaite K Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406 [TBL] [Abstract][Full Text] [Related]
11. Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment. Qiao G; Chen M; Mohammadpour H; MacDonald CR; Bucsek MJ; Hylander BL; Barbi JJ; Repasky EA Cancer Immunol Res; 2021 Jun; 9(6):651-664. PubMed ID: 33762351 [TBL] [Abstract][Full Text] [Related]
14. Engineering strategies for broad application of TCR-T- and CAR-T-cell therapies. Watanabe K; Nishikawa H Int Immunol; 2021 Oct; 33(11):551-562. PubMed ID: 34374779 [TBL] [Abstract][Full Text] [Related]
15. Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies. Zhang ZZ; Wang T; Wang XF; Zhang YQ; Song SX; Ma CQ Pharmacol Res; 2022 Jan; 175():106036. PubMed ID: 34920118 [TBL] [Abstract][Full Text] [Related]
16. IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy. Lee KJ; Choi D; Tae N; Song HW; Kang YW; Lee M; Moon D; Oh Y; Park S; Kim JH; Jeong S; Yang J; Park U; Hong DH; Byun MS; Park SH; Sohn J; Park Y; Im SK; Choi SS; Kim DH; Lee SW Cell Rep Med; 2024 May; 5(5):101567. PubMed ID: 38744277 [TBL] [Abstract][Full Text] [Related]
17. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes. Duong MN; Erdes E; Hebeisen M; Rufer N J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351 [TBL] [Abstract][Full Text] [Related]
18. Akt signaling is critical for memory CD8 Rogel A; Willoughby JE; Buchan SL; Leonard HJ; Thirdborough SM; Al-Shamkhani A Proc Natl Acad Sci U S A; 2017 Feb; 114(7):E1178-E1187. PubMed ID: 28137869 [TBL] [Abstract][Full Text] [Related]
19. [T cell-based immunotherapies in solid tumors]. Baulu E; Dougé A; Chuvin N; Bay JO; Depil S Bull Cancer; 2021 Oct; 108(10S):S96-S108. PubMed ID: 34920813 [TBL] [Abstract][Full Text] [Related]
20. Solid Tumors Challenges and New Insights of CAR T Cell Engineering. Tahmasebi S; Elahi R; Esmaeilzadeh A Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]